Jpn J Cancer Oncol Res | Volume 1, Issue 1 | Research Article | Open Access

Docetaxel-Based Doublet Versus Pemetrexed-Based Doublet as Second-Line Therapy

Chuying Huang1,4, Li Wang2, Jiawei Lu3, Dian Chen1, Hua Yang4* and Chunyan Duan1*

1Departments of Medical Oncology, University Hospital of Hubei University for Nationalities, China
2Department of Dermatology, Dermatology Enshi Tujia and Miao Autonomous Prefecture Central Hospital, China
3Department of Radiotherapy and Oncology, The Second Affiliated Hospital of Soochow University, China
4Department of Respiration, University Hospital of Hubei University for Nationalities, China

*Correspondance to: Chunyan Duan 

Fulltext PDF


This research aims to investigate the comparative effectiveness and safety of docetaxel-based versus pemetrexed-based doublet as second-line therapy in EGFR TKI treated NSCLC patients with EGFR mutations. Sixty-nine patients without T790M mutation who failed EGFR TKI therapy received second-line cytotoxic chemotherapy. Thirty-eight patients treated with a docetaxel-based doublet and 31 patients were treated using pemetrexed-based doublet. Little difference of overall response rate could be found between the two arms (docetaxel-based doublet vs pemetrexed-based doublet: 15.79% vs 19.35%; p=0.473). No complete responses were observed in both arms. Median progression free survival was 3.5 months in the docetaxel-based doublet group and 5.1 months in the pemetrexed-based group (p=0.0029). There was no statistical difference of OS between the two groups (p=0.1019). No significant differences were observed between the two arms in terms of hematological toxicity, with the exception of leucopenia which was more pronounced in the docetaxel-based doublet (p=0.007). Our findings in this study indicated that the Pemetrexed-based doublet showed an improvement in PFS compared with docetaxel-based doublet in NSCLC patients with EGFR mutations who failed first-line EGFR TKI treatment.


Docetaxel; Pemetrexed; EGFR mutations; Tyrosine kinase inhibitors


Huang C, Wang L, Lu J, Chen D, Yang H, Duan C. Docetaxel-Based Doublet Versus Pemetrexed-Based Doublet as Second-Line Therapy. Jpn J Cancer Oncol Res. 2018; 1(1): 1002.

Subscribe to Our Newsletter